Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Purpose: Women at familial/genetic ovarian cancer risk often undergo screening despite unproven efficacy. Research suggests each woman has her own CA125 baseline; significant increases above this level may identify cancers earlier than standard 6- to 12-monthly CA125 > 35 U/mL. Experimental Design: Data from prospective Cancer Genetics Network and Gynecologic Oncology Group trials, which screened 3,692 women (13,080 woman-screening years) with a strong breast/ovarian cancer family history or BRCA1/2 mutations, were combined to assess a novel screening strategy. Specifically, serum CA125 q3 months, evaluated using a risk of ovarian cancer algorithm (ROCA), detected significant increases above each subject's baseline, which triggered transvaginal ultrasound. Specificity and positive predictive value (PPV) were compared with levels derived from general population screening (specificity 90%, PPV 10%), and stage-at-detection was compared with historical high-risk controls. Results: Specificity for ultrasound referral was 92% versus 90% (P = 0.0001), and PPV was 4.6% versus 10% (P > 0.10). Eighteen of 19 malignant ovarian neoplasms [prevalent = 4, incident = 6, risk-reducing salpingo-oophorectomy (RRSO) = 9] were detected via screening or RRSO. Among incident cases (which best reflect long-term screening performance), three of six invasive cancers were early-stage (I/II; 50% vs. 10% historical BRCA1 controls; P = 0.016). Six of nine RRSO-related cases were stage I. ROCA flagged three of six (50%) incident cases before CA125 exceeded 35 U/mL. Eight of nine patients with stages 0/I/II ovarian cancer were alive at last follow-up (median 6 years). Conclusions: For screened women at familial/genetic ovarian cancer risk, ROCA q3 months had better early-stage sensitivity at high specificity, and low yet possibly acceptable PPV compared with CA125 > 35 U/mL q6/q12 months, warranting further larger cohort evaluation. Clin Cancer Res; 23(14); 3628–37. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Domchek, S. M. (2010) · JAMA · doi:10.1001/jama.2010.1237 · Cited by 1,494
Self-citationJacobs, I. J., Menon, U., Ryan, A., Gentry-Maharaj, A., Burnell, M., Kalsi, J. K., Amso, N. N., Apostolidou, S., Benjamin, E., Cruickshank, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01224-6 · Cited by 1,048 · cited 1×
“While even the mixed evidence on the effectiveness of ovarian cancer screening is welcome news (35, 46), we still regard consideration of RRSO upon completion of childbearing and reaching the recommended age as the current standard-of-care for BRCA1/2 mutation carriers.”
BackgroundSelf-citationBurke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955 · cited 2×
“Early detection of ovarian cancer with periodic CA125 blood tests and transvaginal ultrasound (TVU)was recommended in the United States (1, 2), but not universally (3), for women at increased familial risk.”
BackgroundInfluentialNew Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact
Levanon, K., Crum, C., & Drapkin, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1107 · Cited by 412 · cited 1×
“Many high-grade serous ovarian cancers in BRCA1/2 carriers are believed to originate in the distal fimbriated end of the fallopian tube (40), and proteins secreted by fallopian tube epithelium may provide promising biomarker candidates (41).”
BackgroundEvaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.
Kinde, I., Bettegowda, C., Wang, Y., Wu, J., Agrawal, N., Shih, I.-M., Kurman, R., Dao, F., Levine, D. A., Giuntoli, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004952 · Cited by 327 · cited 1×
“Approaches that may enable earlier detection through analysis of DNA in lower genital tract samples are also under investigation (44, 45).”
Background
Cited by
Lheureux, S., Gourley, C., Vergote, I., & Oza, A. M. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32552-2 · Cited by 1,919
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,423
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
Self-citationMenon, U., Gentry-Maharaj, A., Burnell, M., Singh, N., Ryan, A., Karpinskyj, C., Carlino, G., Taylor, J., Massingham, S. K., Raikou, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00731-5 · Cited by 730
Self-citationDiagnosis and Treatment of Ovarian Cancer
Orr, B., & Edwards, R. P. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.07.010 · Cited by 322
Self-citation
Metadata
- Authors
- Skates, S. J., Greene, M. H., Buys, S. S., Mai, P. L., Brown, P., Piedmonte, M., Rodriguez, G., Schorge, J. O., Sherman, M., Daly, M. B., Rutherford, T., Brewster, W. R., O'Malley, D. M., Partridge, E., Boggess, J., Drescher, C. W., Isaacs, C., Berchuck, A., Domchek, S., Davidson, S. A., Edwards, R., Elg, S. A., Wakeley, K., Phillips, K.-A., Armstrong, D., Horowitz, I., Fabian, C. J., Walker, J., Sluss, P. M., Welch, W., Minasian, L., Horick, N. K., Kasten, C. H., Nayfield, S., Alberts, D., Finkelstein, D. M., & Lu, K. H.
- Venue
- Clinical Cancer Research
- Published
- 2017-07-13
- Volume
- 23
- Issue
- 14
- Pages
- 3628-3637
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2584307052
- Cited by
- 140
- References
- 5
- FWCI
- 15.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-2750
- The paper
- Skates, S. J., Greene, M. H., Buys, S. S., Mai, P. L., Brown, P., Piedmonte, M., Rodriguez, G., Schorge, J. O., Sherman, M., Daly, M. B., Rutherford, T., Brewster, W. R., O'Malley, D. M., Partridge, E., Boggess, J., Drescher, C. W., Isaacs, C., Berchuck, A., Domchek, S., . . . Lu, K. H. (2017). Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-2750
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.